Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial

Evaluation of new drug combinations is needed to improve patients' prognosis in advanced hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the safety and efficacy of the capecitabine–oxaliplatine combination (XELOX) in HCC patients. First-line chemotherapy with XELOX reg...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Boige, V, Raoul, J-L, Pignon, J-P, Bouché, O, Blanc, J-F, Dahan, L, Jouve, J-L, Dupouy, N, Ducreux, M
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2007
Gaiak:
Clinical Study
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360397/
https://ncbi.nlm.nih.gov/pubmed/17876335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603956
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak